(Q57601861)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22289050%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

title

Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22289050%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22289050%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Mar Tintoré

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22289050%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Jaume Sastre Garriga

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22289050%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Carmen Tur

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22289050%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Xavier Montalban

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22289050%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

author name string

C Nos

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22289050%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

J Castilló

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22289050%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

M Comabella

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22289050%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

publication date

31 January 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22289050%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Neurology

21 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22289050%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22289050%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22289050%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

page(s)

899-904

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22289050%20AND%20SRC:MED&resulttype=core&format=json

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2011.03648.X

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2011.03648.X

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2011.03648.X

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2011.03648.X

Predicting responders to therapies for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2011.03648.X

Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2011.03648.X

Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2011.03648.X

Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2011.03648.X

Switching multiple sclerosis patients with breakthrough disease to second-line therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2011.03648.X

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2011.03648.X

The OPTimization of Interferon for MS Study: 375 μg interferon beta-1b in suboptimal responders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2011.03648.X

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2011.03648.X

Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2011.03648.X

Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2011.03648.X

A method for evaluating treatment switching criteria in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2011.03648.X

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2011.03648.X

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2011.03648.X

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2011.03648.X

Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2011.03648.X

Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2011.03648.X

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2011.03648.X

10.1111/J.1468-1331.2011.03648.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22289050%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference